drugset / Trial / NCT06639087

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

NCT06639087

Phase 1 Terminated 8 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment.

Timeline

Start
2024-09-27
Primary completion
2025-05-29
Completion
2025-05-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD5462 Unknown
Comparator Dapagliflozin Small molecule